|Bid||6.98 x 2200|
|Ask||6.99 x 900|
|Day's Range||6.72 - 7.07|
|52 Week Range||2.78 - 9.02|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.33|
Quotient (QTNT) delivered earnings and revenue surprises of -48.65% and 14.25%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Eysins, Jersey-based company said it had a loss of 55 cents. The blood test developer posted revenue of $7.9 million in the period. Quotient shares have risen 55 percent since ...
$48.8 million of proceeds from warrant exercises received through July 31 $36 million of additional senior notes issued and funded in June Initial SDS microarray verification and validation started Record ...
JERSEY, Channel Islands, July 24, 2018-- Quotient Limited, a commercial-stage diagnostics company, today announced that financial results for its fiscal first quarter ended June 30, 2018, will be released ...
Following the recent announcement of positive field trial data in a European field trial, the Company met earlier today with investors and analysts at NASDAQ’s headquarters to provide an update on the progress towards the commercialization of MosaiQ. Information presented included a demonstration of the features of the MosaiQ instrument designed to bring automated high throughput microarray based diagnostic testing to transfusion diagnostics and beyond. Franz Walt, Quotient’s CEO, presented the Quotient strategy for MosaiQ and the unique opportunity in the large transfusion diagnostics market. In addition, a voice of customer video described that market’s urgent need for innovation. Jeremy Stackawitz, the Company’s President of Commercial, explained how MosaiQ’s unique product design is expected to meet the stated need of customers in an affordable automated format designed to deliver value through a reduction in the total cost of ownership when compared to currently available solutions.
Quotient Limited (QTNT), a commercial-stage diagnostics company (the Company), has completed the offering of up to $120.0 million aggregate principal amount of its 12% Senior Secured Notes due 2023 (the “Notes”). On June 29, 2018, the Company, completed the second and final closing (the “Second Closing”) of its offering of the Notes. Upon the Second Closing, the Company issued an additional $36.0 million aggregate principal amount of the Notes (the “Additional Notes”).
Stock Research Monitor: QTNT, ADMP, and PETS LONDON, UK / ACCESSWIRE / June 28, 2018 / If you want a free Stock Review on VRX sign up now at www.wallstequities.com/registration . On Wednesday, June 27, ...
Quotient Limited’s (NASDAQ:QTNT): Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The US$402.65m market-cap companyRead More...
On a per-share basis, the Eysins, Jersey-based company said it had a loss of 44 cents. The blood test developer posted revenue of $6.1 million in the period. For the year, the company reported that its ...
Understanding how Quotient Limited (NASDAQ:QTNT) is performing as a company requires looking at more than just a years’ earnings. Today I will run you through a basic sense check toRead More...